Plural Ring Oxygens In The Hetero Ring Patents (Class 514/452)
-
Patent number: 8815939Abstract: The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse and as neuroprotective agents. The present invention is further directed to a process for the preparation of the novel substituted sulfamide derivatives.Type: GrantFiled: July 14, 2009Date of Patent: August 26, 2014Assignee: Janssen Pharmaceutica NVInventors: David F. McComsey, Michael H. Parker
-
Patent number: 8809385Abstract: The present invention is directed to a novel crystalline form of (2S)-(?)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine; obesity; pain; substance abuse; or for neuroprotection. The present invention is further directed to a process for the preparation of the novel crystalline form.Type: GrantFiled: June 19, 2009Date of Patent: August 19, 2014Assignee: Janssen Pharmaceutica NVInventors: Steven J. Mehrman, Wenju Wu
-
Patent number: 8802722Abstract: Provided are benzopyran compounds of formula I, for example, pomiferin-3?,4?-dimethyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. wherein R3, R4, R5, R6, R7 and R8 are described herein. Also provided are plant extracts containing a compound of formula I, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.Type: GrantFiled: January 27, 2012Date of Patent: August 12, 2014Assignee: New York UniversityInventor: Seth J. Orlow
-
Publication number: 20140219995Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.Type: ApplicationFiled: July 13, 2012Publication date: August 7, 2014Applicant: MICROBIOTIX, INC.Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams, Matthew Torhan
-
Patent number: 8791155Abstract: The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.Type: GrantFiled: September 26, 2011Date of Patent: July 29, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Bing Wang, Gail Walkinshaw, Donald R. James
-
Publication number: 20140194497Abstract: Provided is a composition for scalp and hair treatment, including a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness, or hair thinness.Type: ApplicationFiled: February 6, 2014Publication date: July 10, 2014Applicant: R-TECH Ueno, Ltd.Inventors: Masato IINO, Satoshi YAMAKI, Satoshi NAKANISHI, Masahiro TAJIMA, Ryuji UENO
-
Publication number: 20140179773Abstract: The present invention concerns the field of heart related disorders in NAFLD patients, and in particular relates to a method of treatment suitable for improving the conditions of heart injury and myocardial related damage in such patients. Cardiovascular diseases (CVD), including coronary heart disease and non-ischemic cardiomyopathy, are the leading cause of death in patients with NAFLD Silibinin administration markedly demonstrated an effectiveness on myocardial damage and an improvement of the myocardiocyte function reversing the accumulation of lipid droplets and consequently improving the condition of these patients.Type: ApplicationFiled: December 20, 2012Publication date: June 26, 2014Applicant: Instituto Biochimico Italiano Giovanni Lorenzini S.p.A.Inventor: Federico Salamone
-
Publication number: 20140179687Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.Type: ApplicationFiled: February 21, 2014Publication date: June 26, 2014Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michael Pawlotsky
-
Publication number: 20140171496Abstract: The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.Type: ApplicationFiled: February 7, 2014Publication date: June 19, 2014Applicant: R-Tech Ueno, Ltd.Inventors: Ryuji UENO, Tsuyoshi HABE, Takashi SEKIDA
-
Publication number: 20140161830Abstract: Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.Type: ApplicationFiled: November 25, 2013Publication date: June 12, 2014Applicant: Massachusetts Institute of TechnologyInventors: Daniel Griffith Anderson, Kathryn Ann Whitehead, Joseph R. Dorkin, Arturo Jose Vegas, Yunlong Zhang
-
Patent number: 8741905Abstract: The invention relates to a compound of Formula I:Type: GrantFiled: May 6, 2013Date of Patent: June 3, 2014Assignees: The Broad Institute, Inc., President and Fellows of Harvard CollegeInventors: Bridget Wagner, Jeremy Duvall, Danny Hung-Chieh Chou
-
Patent number: 8716180Abstract: The present invention provides a method of reducing mycotoxin contamination of a plant and/or harvested plant material, said method comprising treating plant propagation material with one or more fungicides, germinating or growing said plant propagation material to produce a plant, and harvesting plant material from said plant.Type: GrantFiled: June 28, 2006Date of Patent: May 6, 2014Assignee: Syngenta Crop Protection LLCInventors: Edmond Sztor, Pascal Poels, Michael Oostendorp, Franz Brandl
-
Patent number: 8716231Abstract: The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) or formula (II) as described herein.Type: GrantFiled: December 18, 2006Date of Patent: May 6, 2014Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, Allen B. Reitz
-
Patent number: 8716527Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2- substituted-p-quinone derivatives as disclosed herein.Type: GrantFiled: March 4, 2009Date of Patent: May 6, 2014Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
-
Publication number: 20140121246Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.Type: ApplicationFiled: October 15, 2013Publication date: May 1, 2014Applicant: Metabolex, Inc.Inventors: Dong Fang Shi, Jiangao Song, Christopher J. Rabbat, Jingyuan Ma, Aaron Novack, Imad Nashashibi, Xin Chen
-
Publication number: 20140105864Abstract: Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-?, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: CM & D PHARMA LIMITEDInventor: Alfredo DI LEO
-
Patent number: 8691867Abstract: The present invention is a method for the treatment of alcohol abuse and/or addiction comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and/or formula (II) as herein defined.Type: GrantFiled: December 18, 2006Date of Patent: April 8, 2014Assignee: Janssen Pharmaceutica NVInventors: Virginia L. Smith-Swintosky, Allen B. Reitz
-
Publication number: 20140093503Abstract: The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the abeo-taxanes.Type: ApplicationFiled: April 6, 2012Publication date: April 3, 2014Applicant: Arbor Therapeutics, LLCInventors: James D. McChesney, John T. Henry, Sylesh Venkataraman, Mahesh Kumar Gundluru
-
Publication number: 20140094493Abstract: A compound of Formula (I), and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein R1 is independently selected from F, Cl, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alkyl, C1-4alkoxy, CONH2 (optionally mono- or di-substituted by C1-4alkyl) and SO2NH2, R2 is independently selected from C1-6allkyl substituted by R3 wherein the C1-6alkyl chain optionally comprises one or two heteroatoms select from O; R3 is selected from aryl, C3-6cycloalkyl, C3-6heterocyclyl and C3-6heteroaryl, wherein the heterocyclyl and heteroaryl rings are nitrogen containing; and wherein R3 is optonally substituted by one or more groups selected from R1; n1 is zero or an integer from 1 to 2; n2 is an integer from 1 to 2; and the sum of n1 and 2 is less than or equal to 2; R5 is selected from any group defined for R1 and R2; R6a and R6b are independently selected from H or C1-4alkyl; R7 is independently selected from F, Cl, Br, CN, NH2, OH, CHO, COOH, oxo, C1-4alType: ApplicationFiled: February 6, 2012Publication date: April 3, 2014Inventors: Jillian G. Baker, Peter M. Fischer, Christophe Fromont, Sheila M. Gardiner, Stephen J. Hill, Gopal Jadhav, Barrie Kellam, Shailesh Mistry, Jeanette Woolard
-
Patent number: 8685978Abstract: Novel 3?-deoxy-3?-acylaminospectinomycin compounds are described. Also described are methods of using the 3?-deoxy-3-acylaminospectinomycin compounds and other spectinomycin analogs in treating tuberculosis and in treating microbial infections.Type: GrantFiled: July 26, 2010Date of Patent: April 1, 2014Assignee: University of Tennessee Research FoundationInventors: Richard E. Lee, Jianjun Qi, Julian G. Hurdle, Bernd Meibohm, Vnr Pavan Kumar Vaddady, Rakesh, Jiuyu Liu
-
Patent number: 8686048Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.Type: GrantFiled: May 5, 2011Date of Patent: April 1, 2014Assignee: Rhizen Pharmaceuticals SAInventors: Meyyappan Muthuppalaniappan, Prashant K. Bhavar, Srikant Viswanadha, Swaroop Kumar V. S. Vakkalanka, Gayatri S. Merikapudi
-
Publication number: 20140088079Abstract: The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.Type: ApplicationFiled: June 1, 2012Publication date: March 27, 2014Applicant: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon KIM, Dong Ho Hong, Misuk Kang
-
Patent number: 8680300Abstract: The present invention relates to compounds with a dioxane nucleus derived from carbohydrates and C-glucosides, process for obtaining same, to the use of such compounds as cytotoxic and antiproliferative agents and to the use thereof for producing a cancer treatment drug.Type: GrantFiled: June 25, 2010Date of Patent: March 25, 2014Assignees: Universidad de la Laguna, Consejo Superior de Investigaciones CientificasInventors: Alicia Boto Castro, Rosendo Hernández González, Dácil Hernández Mesa, Eleuterio Álvarez González, Raquel Marín Cruzado, Mario Diaz González
-
Publication number: 20140080902Abstract: The present invention discloses ?-diketones, ?-diketones or ?-hydroxyketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.Type: ApplicationFiled: November 21, 2013Publication date: March 20, 2014Applicant: Samumed, LLCInventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
-
Patent number: 8673965Abstract: Disclosed is a composition for treating arthritis containing a dibenzo-p-dioxin derivative as an active ingredient. This dibenzo-p-dioxin derivative is very effective in inhibiting NF-kB and AP-1 activity, alleviates the symptoms of degenerative arthritis and rheumatoid arthritis without irritating the skin or causing side effects, and can continue to exhibit improvement effects for a considerable period of time after discontinuation of treatment. Additionally, when the dibenzo-p-dioxin derivative is contained in liposomes, the composition of the invention exhibits much greater effects on treating arthritis by absorption through skin, and thus is useful for the treatment of degenerative arthritis and rheumatoid arthritis.Type: GrantFiled: November 29, 2012Date of Patent: March 18, 2014Assignee: Livechem, Inc.Inventors: Haeng Woo Lee, Hyeon Cheol Shin, Seoung Ho Kim, Yong Ju Park
-
Publication number: 20140073662Abstract: The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.Type: ApplicationFiled: November 22, 2013Publication date: March 13, 2014Applicant: SanofiInventors: Manfred SCHUDOK, Michael WAGNER, Armin BAUER, Anna KOHLMANN
-
Publication number: 20140072664Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.Type: ApplicationFiled: May 17, 2012Publication date: March 13, 2014Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Jae Wha Kim, Kyung Seop Ahn, Ho Bum Kang, Sei Ryang Oh, Jae Jong Go, Joo Heon Kim, Jang Mi Sun, Jae Sung Song, Hyun Woo Oh, Da Jung Ji
-
Publication number: 20140073501Abstract: A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Inventors: Ratnakar Asolkar, Marja Koivunen, Pamela Marrone
-
Publication number: 20140045903Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.Type: ApplicationFiled: July 30, 2013Publication date: February 13, 2014Applicant: Intrexon CorporationInventors: Robert Eugene HORMANN, David W. Potter, Orestes Chortyk, Colin M. Tice, Glenn Richard Carlson, Andrew Meyer, Thomas R. Opie
-
Publication number: 20140038951Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: January 15, 2013Publication date: February 6, 2014Applicant: OMEROS CORPORATIONInventors: Neil S. Cutshall, Jennifer Lynn Gage, Thomas Neil Wheeler
-
Publication number: 20140031341Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.Type: ApplicationFiled: December 19, 2011Publication date: January 30, 2014Applicants: UNIVERSITAT MUNSTER, GALDERMA RESEARCH & DEVELOPMENTInventors: Jerome Aubert, Martin Steinhoff
-
Publication number: 20140031338Abstract: The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.Type: ApplicationFiled: April 13, 2012Publication date: January 30, 2014Applicant: LABORATOIRE BIODIMInventors: Sophie Chasset, Francis Chevreuil, Benoit Ledoussal, Frédéric Le Strat, Richard Benarous
-
Publication number: 20140023699Abstract: The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.Type: ApplicationFiled: July 25, 2013Publication date: January 23, 2014Inventors: James D. McChesney, Gilles H. Tapolsky, David Lloyd Emerson, John Marshall, Tauseef Ahmed, Allen Cohn, Michael Kurman, Manuel R. Modiano
-
Publication number: 20140018414Abstract: The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.Type: ApplicationFiled: March 14, 2013Publication date: January 16, 2014Inventor: Robert J. Brosnan
-
Publication number: 20140005228Abstract: The present invention discloses ?-diketones, ?-diketones or ?-hydroxyketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.Type: ApplicationFiled: September 5, 2013Publication date: January 2, 2014Applicant: Samumed, LLCInventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
-
Publication number: 20130345195Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.Type: ApplicationFiled: August 23, 2013Publication date: December 26, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Asitha ABEYWARDANE, Michael J. BURKE, Thomas Martin KIRRANE, Matthew Russell NETHERTON, Anil Kumar PADYANA, Lana Louise SMITH KEENAN, Hidenori TAKAHASHI, Michael Robert TURNER, QIANG ZHANG, Qing ZHANG
-
Publication number: 20130338218Abstract: The present invention relates to a HIV-1 inhibiting pharmaceutical composition containing, as an active ingredient, 6,6?-bieckol which is a phloroglucinol polymer compound separated from Ecklonia cava. The Ecklonia cava-derived 6,6?-bieckol according to the present invention inhibits HIV-1 induced cell fusion, the cell lysis effect, and the cytopathogenic effect including virus p24 antibody production, exhibits RT enzyme inhibition activity and HIV-1 infection inhibition activity, and shows no cytotoxicity at the concentration that almost perfectly inhibits HIC-1 replication.Type: ApplicationFiled: August 12, 2013Publication date: December 19, 2013Applicant: Pukyong National University Industry - Academic Cooperation FoundationInventors: Moon-Moo KIM, Se-Kwon KIM, Sang-Hoon LEE
-
Publication number: 20130338217Abstract: There is provided an antibiotic composition including Eisenia bicyclis-derived phlorotannin compound, in which the antibiotic composition includes a phlorotannin compound selected from 7-phloroeckol, fucofuroeckol-A, and dioxinodehydroeckol, or mixture thereof, which are derived from Eisenia bicyclis, as an effective component. The compounds described above exhibit an antibiotic activity against an antibiotic-resistant bacterium. In addition, the compound described above can exhibit a synergetic effect by using in combination with ?-lactam-based antibiotic composition by recovering an antibiotic activity of ?-lactam-based antibiotic, such as ampicillin, penicillin, and oxacillin against MRSA.Type: ApplicationFiled: October 30, 2012Publication date: December 19, 2013Applicant: Pukyong National University Industry-University Cooperation FoundationInventors: Se-Kwon KIM, Young-Mog Kim, Myung-Suk Lee, Sung-Hwan Eom
-
Publication number: 20130336993Abstract: Methods for identifying compounds that modulate the generation of regulatory T cells (Treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of Foxp3.Type: ApplicationFiled: January 18, 2013Publication date: December 19, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Howard Weiner, Francisco J. Quintana
-
Patent number: 8609717Abstract: The present invention discloses ?-diketones, ?-diketones or ?-hydroxyketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.Type: GrantFiled: August 17, 2011Date of Patent: December 17, 2013Assignee: Samumed, LLCInventors: Sunil Kumar KC, David Mark Wallace, John Hood, Charlene F. Barroga
-
Publication number: 20130331427Abstract: The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: October 25, 2012Publication date: December 12, 2013Applicant: Blanchette Rockefeller Neuroscience InstituteInventor: Blanchette Rockefeller Neuroscience Institute
-
Patent number: 8604021Abstract: The invention relates to 5-HT6 receptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.Type: GrantFiled: May 10, 2011Date of Patent: December 10, 2013Inventors: Oren Becker, Rosa Melendez, Yael Marantz, Anurag Sharadendu, Merav Fichman, Mercedes Lobera, Hanoch Senderowitz, Srinivasa Rao Cheruku, Sharon Shacham, Laurence Wu, Ashis Saha, Pini Orbach, Dale S. Dhanoa
-
Patent number: 8604077Abstract: Novel ketal compounds can be made from an oxocarboxylate and a triol. Novel polymeric structures are, in turn, synthesized from the ketal compounds. Such ketal compounds and associated polymers are useful in a broad range of applications as a substitute for materials derived from petroleum or other such nonrenewable resources.Type: GrantFiled: September 4, 2008Date of Patent: December 10, 2013Assignee: Segetis, Inc.Inventors: Douglas Alan Wicks, Charles Todd Williams, Sergey A. Selifonov
-
Publication number: 20130316906Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, R4, R5, Y, Q and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as herbicides and/or pesticides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as pesticides and/or for preventing unwanted plant growth.Type: ApplicationFiled: October 28, 2011Publication date: November 28, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Alfred Angermann, Stefan Lehr, Guido Bojack, Reiner Fischer, Isolde Häuser-hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Arnd Voerste, Dieter Feucht
-
Publication number: 20130317043Abstract: The invention relates to a compound of Formula I:Type: ApplicationFiled: May 6, 2013Publication date: November 28, 2013Applicants: President and Fellows of Harvard College, The Broad Institute, Inc.Inventors: The Broad Institute, Inc., President and Fellows of Harvard College
-
Publication number: 20130310329Abstract: There is disclosed a combination of inhibitors of Tissue Transglutaminase (TG2), inhibitors of reactive oxygen species (ROS) and CFTR channel activators (potentiators) for separate, sequential or simultaneous administration to CF patients carrying the ?F508-CFTR mutation, and pharmaceutical compositions thereof.Type: ApplicationFiled: May 16, 2013Publication date: November 21, 2013Applicant: I.E.R.F.C. EUROPEAN INSTITUTE FOR CYSTIC FIBROSIS RESEARCHInventor: I.E.R.F.C. European Institute For Cystic Fibrosis Research
-
Publication number: 20130303466Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: November 14, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
-
Publication number: 20130303544Abstract: The present invention provides a kind of benzopyrone compounds having a structure of formula (I) and the pharmaceutically acceptable salts or prodrugs thereof, and the pharmaceutical compositions containing such compounds, which can be used to regulate the novel estrogen receptor ER-a36, and prevent and/or treat the related diseases mediated by the ER-a36 receptor, such as cancers, etc.Type: ApplicationFiled: December 21, 2011Publication date: November 14, 2013Applicant: BEIJING SHENOGEN PHARMA GROUP LTD.Inventors: Hongxia Ding, Kun Meng, Jin Li
-
Publication number: 20130303601Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.Type: ApplicationFiled: April 3, 2013Publication date: November 14, 2013Inventors: James D. McChesney, John T. Henri, Sylesh Kumar Venkataraman, Mahesh Kumar Gundluru
-
Patent number: 8569358Abstract: Describe is a method of administering to a subject silymarin, or of the main constituents thereof alone or as a mixture, chosen from silybin (or 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3, 5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxine), isosilybin, silydianin, silychristin, silandrin, silymonin and taxifolin, isolated enantiomers thereof and also salts thereof.Type: GrantFiled: February 13, 2006Date of Patent: October 29, 2013Assignees: GreenPharma, BioAlternativesInventors: Philippe Bernard, Francois-Xavier Bernard